The Technical Analyst
Eloxx Pharmaceuticals Inc [ELOX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Eloxx Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.52% $0.963
America/New_York / 17 apr 2024 @ 11:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.03 mill |
| EPS: | -8.88 |
| P/E: | -0.110 |
| Earnings Date: | Apr 17, 2024 |
| SharesOutstanding: | 3.14 mill |
| Avg Daily Volume: | 0.0092 mill |
| RATING 2024-04-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.110 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.110 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.69 (179.27%) $1.725 |
| Date: 2024-04-17 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.861 - 1.065 ( +/- 10.60%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-24 | Walts Alan Edmund | Buy | 7 500 | Restricted Stock Units |
| 2024-01-24 | Rubin Steven D | Buy | 7 500 | Restricted Stock Units |
| 2024-01-24 | Androski Lindsay | Buy | 7 500 | Restricted Stock Units |
| 2024-01-24 | Aggarwal Sumit | Buy | 60 000 | Restricted Stock Units |
| 2023-01-30 | Walts Alan Edmund | Buy | 2 859 | Stock Options (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 94 transactions |
| Buy: 28 846 630 | Sell: 836 099 |
Forecast:
13:30 - $0.973
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.963 (-2.52% ) |
| Volume | 0.0108 mill |
| Avg. Vol. | 0.0092 mill |
| % of Avg. Vol | 118.00 % |
| Signal 1: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ELOX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ELOX
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Latest Press Releases
2024-04-16 07:30:00 - Press Release
Eloxx Pharmaceuticals Provides Elx-02 And Zkn-013 Program Updates
Elx-02 granted orphan drug designation (odd) from u.s. food and drug administration (fda) for treatment of alport syndrome
2024-03-13 11:42:00 - Press Release
Almirall And Eloxx Pharmaceuticals Enter Into Exclusive Agreement To License Zkn-013 For Rare Dermatological Diseases
Barcelona, spain and watertown, mass., march 13, 2024 (globe newswire) -- almirall, s.a. (bme:alm) and eloxx pharmaceuticals, inc. (otc: elox) announced today that the companies have entered into an exclusive license agreement for the asset zkn-013. under the agreement, almirall obtains global rights to develop and commercialize zkn-013, including for the use in orphan dermatological diseases. zkn-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.
2024-03-13 11:33:00 - Press Release
Almirall And Eloxx Pharmaceuticals Enter Into Exclusive Agreement To License Zkn-013 For Rare Dermatological Diseases
Barcelona, spain & watertown, mass.--(business wire)--almirall, s.a. (bme:alm) and eloxx pharmaceuticals, inc. (otc: elox) announced today that the companies have entered into an exclusive license agreement for the asset zkn-013. under the agreement, almirall obtains global rights to develop and commercialize zkn-013, including for the use in orphan dermatological diseases. zkn-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce funct.
2023-11-13 16:15:00 - Press Release
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial And Operating Results And Provides Business Update
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its phase 2 open-label clinical trial of elx-02 for the treatment of alport syndrome
2023-10-09 08:00:00 - Press Release
Eloxx Pharmaceuticals Reports Additional Confirmation That All Nonsense Mutation Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement In Kidney Morphology And Clinical Benefit Of Reduction Or Stabilization Of Proteinuria
Elx-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by nipoka gmbh
Latest News
2023-12-05 08:48:19 - InvestorPlace
Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
While getting kicked off an exchange typically signals about the biggest warning sign you can possibly receive, a (somewhat) rational argument exists for delisted stocks to buy. Psychologically, companies go through much anxiety doing whatever they can to stay listed in a major exchange.
2023-07-12 10:52:07 - MarketBeat
This Small Cap Stock Surged Over 100%
Arguably the most impressive mover yesterday was a stock you have probably never heard of. Shares of Eloxx Pharmaceuticals NASDAQ: ELOX rocketed almost 100% yesterday after receiving an increased price target from Oppenheimer.
2023-07-11 15:06:16 - PennyStocks
Penny Stocks to Watch: Why Is ELOX Stock Skyrocketing?
Most traders dream of hitting it big, and penny stocks are some of the most attractive for day traders. It can be any given session where we see at least a handful of cheap stocks under $5 explode.
2023-05-16 08:49:02 - InvestorPlace
Why Is Eloxx Pharmaceuticals (ELOX) Stock Down 27% Today?
Eloxx Pharmaceuticals (NASDAQ: ELOX ) stock is falling hard on Tuesday after the company provided a weak earnings report for Q1 2023. The bad news for ELOX stock starts with its losses per share of $2.88 cents.
2023-05-15 18:59:11 - Zacks Investment Research
Senesco Technologies Inc. (ELOX) Reports Q1 Loss, Lags Revenue Estimates
Senesco Technologies Inc. (ELOX) came out with a quarterly loss of $2.88 per share versus the Zacks Consensus Estimate of a loss of $2.55. This compares to loss of $5.20 per share a year ago.
2023-03-06 16:10:00 - GlobeNewsWire
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13th at 12:00 PM ET.
2023-01-05 09:39:05 - PennyStocks
5 Hot Penny Stocks Exploding After News This Week
Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-09-16 12:48:13 - Zacks Investment Research
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal
Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.
2021-12-17 16:19:55 - PennyStocks
Popular Penny Stocks to Add to Your Watchlist Right Now
Check these three penny stocks out for your list right now The post Popular Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-11-18 14:12:36 - Benzinga
Read Why Eloxx Pharma Stock Continues To Fall
H.C. Wainwright lowered the price target on Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) to $1 from $2 and reiterated a Neutral rating. Analyst Andrew Fein says the ELX-02 top-line data "raises more questions than answers.